De Novo Renal Transplant Recipient.
Conditions
Keywords
Mycophenolate mofetil, Therapeutic Drug Monitoring, Adult kidney transplantation, Paediatric kidney transplantation
Brief summary
Determine the value of a clinically feasible strategy of therapeutic drug monitoring compared with fixed dosing in de novo MMF treated renal transplant recipients with respect to the incidence of treatment failure.
Detailed description
For treatment with mycophenolate mofetil the contribution of TDM still has to be determined, although circumstantial evidence suggests the measurement of mycophenolic acid plasma concentrations adds to patient management. A concerted effort to test the hypothesis that TDM will improve outcome in mycophenolate mofetil therapy in a prospective randomised trial is to be made if we want to have a solid base for the continued measurements of mycophenolic acid concentrations in the future. This trial aims to demonstrate the added value of TDM for mycophenolic acid, by comparing fixed dose treatment with concentration controlled mycophenolate mofetil treatment in kidney transplant recipients.
Interventions
DRUGMycophenolate Mofetil
1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients. Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma.
Sponsors
Hoffmann-La Roche
Erasmus Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Renal transplant recipients who have completed their second birthday, * Recipients from living (related or unrelated), cadaveric (non-heart beating or heart beating) donors, * Single organ recipient (kidney only), * Women of childbearing potential should have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/ml within 1 week prior to beginning MMF treatment. Effective contraception must be used before beginning therapy, during therapy and for 6 weeks following discontinuation of therapy, even where there has been a history of infertility, unless due to hysterectomy, * Patients or patient's parent/guardian providing written informed consent, * Patients co-operative and able to complete all the assessment procedures.
Exclusion criteria
* Patients receiving immunosuppressive therapy (except steroid treatment) within the preceding 28 days, except that immunosuppressive medication may be initiated up to 48 hours before transplantation. Furthermore, all patients should receive 1 g \[adults\] or 600 mg/m2 \[paediatric patients\] of MMF therapy within 6 hours prior to transplantation, * PRA \> 50% within 6 months prior to enrolment, * Cold ischaemia time \>48 hours, * History of malignancy (except localised non-melanotic skin cancer) or the presence of any active malignancy at the time of transplant, * Active peptic ulcer disease, * Active infection, * Mandatory intake of prohibited drugs or it is probable that the patient will require treatment with such drugs after transplant, * Pregnant or lactating females, * Women of child-bearing potential not willing to use a reliable form of contraception, * Patient is allergic or intolerant to polysorbate 80 (TWEEN), phenylalanine (aspartame), steroids, MMF, MPA, tacrolimus or cyclosporin, * Patient or donor with positive tests for HIV or hepatitis B surface antigen, * Patients with liver cirrhosis or clinical evidence of portal hypertension or other indication of moderate or severe liver disease. (Note: it is strongly recommended that patients with hepatitis C have a liver biopsy performed prior to transplantation), * Incompatible ABO blood type and/or positive crossmatch, * Patient has any form of substance abuse, psychiatric disorder or condition, which, in the opinion of the investigator, may invalidate communication with the investigator or with study procedures, * Patients whose laboratory results reveal severe anaemia (as defined by a haemoglobin value \<6 mmol/L \[9.7 g/dL\] for adults receiving erythropoietin, \<4.1 mmol/L \[6.6 g/dL\] for paediatric patients \[regardless of erythropoietin treatment\]), leukopenia (as defined by a WBC value of \<2500/mm3) or thrombocytopenia (as defined by a platelet count of \<75,000/mm3).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment failure including the occurrence of the first one of any of the following: biopsy-proven acute rejection, graft loss, death or discontinuation of MMF therapy during the first 12 months following transplantation. | 12 Months |
Secondary
| Measure | Time frame |
|---|---|
| Time to first acute rejection, | 12 Months |
| Number of acute rejection episodes per patient in the first year post-transplantation, | 12 Months |
| Overall treatment outcome at 12 months post-transplantation which is composed of any one of the following: | 12 Months |
| Proportion of patients treated for acute rejection during the first 3, 6, 12 months post-transplantation, | 3, 6 and 12 Months |
| Death, | 12 Months |
| Discontinuation of MMF therapy, | 12 Months |
| Patient lost to follow-up. | 12 Months |
| Graft loss, | 12 Months |
Countries
Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Estonia, France, Germany, Lithuania, Netherlands, Norway, Poland, Spain, Sweden, Taiwan, United Kingdom, Venezuela
Outcome results
None listed